A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

Clément François (1) , Alice Guiraud-Diawara , Christophe Lançon (2) , Pierre Michel Llorca (3) , Ann Hartry , Lene Hammer-Helmich , Djamel Zighed (4) , Adrian Tanasescu (5) , Mondher Toumi (6)

1 Lundbeck SAS
2 Hôpitaux Sud - Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM]
3 NPsy-Sydo - Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux
4 UL2 - Université Lumière - Lyon 2
5 ISH - Institut des Sciences de l'Homme
6 Pharmaco-Epidémiologie

Domaines: Neurosciences; Neurobiologie; Psychologie et comportements; Sciences cognitives

Clément François, Alice Guiraud-Diawara, Christophe Lançon, Pierre Michel Llorca, Ann Hartry, et al.. A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting. Journal of Market Access & Health Policy, 2017, 5 (1), ⟨10.1080/20016689.2017.1372026⟩. ⟨hal-01696896⟩